Correction to: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Sarin, Shiv Kumar; Choudhury, Ashok; Sharma, Manoj Kumar; Maiwall, Rakhi; Mahtab, Mamun Al; Rahman, Salimur; Saigal, Sanjiv; Saraf, Neeraj; Soin, Arvinder S.; Devarbhavi, Harshad; Kim, Dong Joon; Dhiman, Radha K.; Duseja, Ajay; Taneja, Sunil; Eapen, C E; Goel, Ashish; Ning, Qin; Chen, Tao; Ma, Ke; Duan, Zhongping; Chen, Yu; Treeprasertsuk, Sombat; Salehiniya, Hamid; Butt, Amna Subhan; Jafri, Wasim; Shukla, Akash; Saraswat, Vivek A.; Tan, Soek Siam; Sood, Ajit; Midha, Vandana; Goyal, Omesh; Ghazinyan, Hasmik; Arora, Anil; Hu, Jinhua; Sahu, Manoj Kumar; Rao, Pragna; Lee, Guan Huei; Lim, Seng Gee; Lesmana, Laurentius A.; Lesmana, Cosmas Rinaldi Adithya; Shah, Samir; Prasad, V G Mohan; Payawal, Diana A.; Abbas, Zaigham; Dokmeci, A. Kadir; Sollano, José D.; Carpio, Gian; Shresta, Ananta; Lau, Gkk; Karim, Fazal; Shiha, Gamal; Gani, Rino Alvani; Kalista, Kemal Fariz; Yuen, Man‐Fung; Alam, Seema; Khanna, Rajeev; Sood, Vikrant; Lal, Bikrant Bihari; Pamecha, Viniyendra; Jindal, Ankur; Rajan, V.; Arora, Vinod; Yokosuka, Osamu; Niriella, Madunil Anuk; Li, Hai; Qi, Xiaolong; Tanaka, Atsushi; Mochida, Satoshi; Chaudhuri, Dominic Ray; Gane, Ed; Win, Khin Maung; Chen, Wei Ting; Rela, M; Kapoor, Dharmesh; Rastogi, Amit; Kale, Pratibha; Rastogi, Archana; Sharma, Chhagan Bihari; Bajpai, Meenu; Singh, Virender; Premkumar, Madhumita; Maharashi, Sudhir; Olithselvan, Arikichenin; Philips, Cyriac Abby; Srivastava, Anshu; Yachha, Surender Kumar; Wani, Zaid Ahmad; Thapa, Babu Ram; Saraya, Anoop; Shalimar, S.; Kumar, Ashish; Wadhawan, Manav; Gupta, Subash; Madan, Kaushal; Sakhuja, Puja; Vij, Vivek; Sharma, Barjesh Chander; Garg, Hitendra; Garg, Vishal; Kalal, Chetan; Anand, Lovkesh; Vyas, Tanmay; Mathur, Rajendra Prasad; Kumar, Guresh; Jain, Priyanka; Pasupuleti, Samba Siva Rao; Chawla, Yogesh; Chowdhury, Abhijit; Alam, Shahinul; Song, Do Seon; Yang, Jin Mo; Yoon, Eileen L.

doi:10.1007/s12072-019-09980-1

Cited by 26 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the accuracy of the new model to predict 90-day mortality rate was compared with the MELD score. The inclusion criteria for the patients were in accordance with the Asian Pacific Association for HBV-ACLF, 9 which was detailed as follows: (a) age not lower than 16 years; (b) hepatitis B virus surface antigen (HBsAg) positivity for at least 6 months; (c) serum bilirubin ≥5 mg/dL (≥85 µmol/L) with a sudden exacerbation of liver disease; (d) international normalized ratio (INR) >1.5; and (e) hepatic encephalopathy (HE) and/or ascites within 28 days. The exclusion standards were as follows: (a) pregnancy or lactation; (b) co-infection with human immunodeficiency virus; (c) severe comorbidities, e.g., previous renal failure, carcinoma, cardiac dysfunctions, etc; (d) other hepatic disorders, like hepatitis A, C or E, autoimmune hepatitis, alcohol consumption, or hereditary liver diseases; or (e) infections that required hospitalization.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Nomogram for 90-day Outcome in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure

Yang¹,

Xue²,

Wu³

et al. 2021

J Clin Transl Hepatol

View full text Add to dashboard Cite

Background and Aims:It is challenging to predict the 90-day outcomes of patients infected with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) via prevailing predictive models. This study aimed to develop an innovative model to enhance the analytical efficacy of 90-day mortality in HBV-ACLF. Methods: In this study, 149 HBV-ACLF patients were evaluated by constructing a death risk prediction nomogram. Bootstrap resampling and an independent validation cohort comprising 31 patients from June 2019 to February 2020 were assessed for model confirmation. Results: The nomogram was constructed by entering and identifying five factors (age, total bilirubin, prothrombin activity (PTA), lymphocyte (L)%, and monocyte (M)%. Healthy refinement was achieved from the nomogram analysis, where the area under the receiver operating characteristic curve was 0.864 for the training cohort and 0.874 was achieved for the validation cohort. There was admirable concordance between the predicted and true results in the equilibrium curve. The decision curve assessment revealed the useful clinical application of the nomogram. Conclusions: We constructed an innovative nomogram and validated it for the prediction of 90-day HBV-ACLF patient outcomes. This model might help develop optimized treat-ment protocol recommendations for HBV-ACLF patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Nomogram for 90-day Outcome in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure

Yang¹,

Xue²,

Wu³

et al. 2021

J Clin Transl Hepatol

View full text Add to dashboard Cite

show abstract

“…The enrolment criteria for these patients corresponded to the Asian Pacific Association for ACLF. 10 The inclusion criteria were as follows: (a) patients who were at least 16 years-old; (b) patients who were HBV surface antigen (HBsAg)-positive for at least 6 months; (c) patients with a total bilirubin (TBIL) of >171 µmol/L and a sudden exacerbation of liver disease; (d) patients with an international normalized ratio (INR) of >1.5; (e) patients who had ascites within 4 weeks and/or had an onset of hepatic encephalopathy (HE). The exclusion criteria were as follows: (a) pregnant or lactating patients; (b) patients co-infected with human immunodeficiency virus; (c) patients with severe diseases, such as heart dysfunction, previous renal failure, cancer, etc.…”

Section: Methodsmentioning

confidence: 99%

Novel Prognostic Models for Predicting the 180-Day Outcome for Patients with Hepatitis-B Virus-related Acute-on-chronic Liver Failure

Xue¹,

Yang²,

Wu³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Background and Aims: It remains difficult to forecast the 180-day prognosis of patients with hepatitis B virus-acuteon-chronic liver failure (HBV-ACLF) using existing prognostic models. The present study aimed to derive novel-innovative models to enhance the predictive effectiveness of the 180day mortality in HBV-ACLF. Methods: The present cohort study examined 171 HBV-ACLF patients (non-survivors, n=62; survivors, n=109). The 27 retrospectively collected parameters included the basic demographic characteristics, clinical comorbidities, and laboratory values. Backward stepwise logistic regression (LR) and the classification and regression tree (CART) analysis were used to derive two predictive models. Meanwhile, a nomogram was created based on the LR analysis. The accuracy of the LR and CART model was detected through the area under the receiver operating characteristic curve (AUROC), compared with model of end-stage liver disease (MELD) scores. Results: Among 171 HBV-ACLF patients, the mean age was 45.17 years-old, and 11.7% of the patients were female. The LR model was constructed with six independent factors, which included age, total bilirubin, prothrombin activity, lymphocytes, monocytes and hepatic encephalopathy. The following seven variables were the prognostic factors for HBV-ACLF in the CART model: age, total bilirubin, prothrombin time, lymphocytes, neutrophils, monocytes, and blood urea nitrogen. The AUROC for the CART model (0.878) was similar to that for the LR model (0.878, p=0.898), and this exceeded that for the MELD scores (0.728, p<0.0001). Conclusions: The LR and CART model are both superior to the MELD scores in predicting the 180-day mortality of patients with HBV-ACLF. Both the LR and CART model can be used as medical decision-making tools by clinicians.

show abstract

“…In addition, based on an institutional decision, intra‐ and interdepartmental pediatric patients with a suspicion of CLD at the level of the consultant were referred to the above pediatric unit. The exclusion criteria for enrollment were presence of hepatic decompensation, pediatric acute liver failure (PALF), 4 or acute‐on‐chronic liver failure (ACLF) 5 at any time during the illness duration or course of hospital stay.…”

Section: Methodsmentioning

confidence: 99%

Clinicohistological correlation of etiological spectrum of chronic liver disease diagnosed during noncirrhotic stages in children: Can need of liver biopsy be obviated?

et al. 2020

View full text Add to dashboard Cite

Background and Aim: Limited data exist regarding the etiological spectrum of the subset of chronic liver diseases (CLDs) diagnosed in noncirrhotic states in children. Our primary objective was to study the clinicoetiological profile of CLDs detected in noncirrhotic stages in children younger than 12 years of age. The secondary objective was to find the hepatic histological correlation of provisional diagnosis by different ranks of doctors. Methods: This was an observational epidemiological study, cross-sectional in design, conducted in a tertiary-care setting over a 2-year period. Results: Thirty-seven cases were enrolled, with a mean ± SD age of 8 ± 4.1 years and a male:female ratio of 1.8:1. Etiologies noted were Wilson disease (n = 8), autoimmune hepatitis (n = 4), secondary hemochromatosis (n = 4), chronic hepatitis B (n = 3), chronic hepatitis C (n = 2), non-alcoholic steatohepatitis (n = 2), progressive familial intrahepatic cholestasis (n = 2), extrahepatic biliary atresia (n = 2), Alagille syndrome (n = 1), galactosemia (n = 1), Gaucher disease (n = 1), Niemann-Pick disease (n = 1), and Budd-Chiari syndrome (n = 1), with an inconclusive diagnosis in five children. Relevant investigations were ordered more frequently by the specialist consultant (SC) and super specialist (SS) combined in comparison with the senior resident (SR) and junior resident (JR) together. (P = 0.0013). Irrelevance of the tests ordered was significantly higher in the junior tier (JR and SR; SR > JR) in contrast to the senior tier of doctors (SC and SS) (P < 0.01). The clinicohistological correlation of an etiological diagnosis significantly differed between the junior and senior ranks of physicians. We noted that an ideal clinical acumen could help to avoid liver biopsy for etiological diagnosis in 78.3% (29/37) of the study population. Conclusion: Interpretation of clinical presentation by the senior set of doctors is preferable, which could obviate the need for liver biopsy regarding diagnosis in a proportion of pediatric CLD patients.

show abstract

Correction to: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update

Cited by 26 publications

References 0 publications

Development and Validation of a Nomogram for 90-day Outcome in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure

Development and Validation of a Nomogram for 90-day Outcome in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure

Novel Prognostic Models for Predicting the 180-Day Outcome for Patients with Hepatitis-B Virus-related Acute-on-chronic Liver Failure

Clinicohistological correlation of etiological spectrum of chronic liver disease diagnosed during noncirrhotic stages in children: Can need of liver biopsy be obviated?

Contact Info

Product

Resources

About